BNCM: DELEX Pharma Secures $4.30 Million Contract for Newly Opened Medical Center.
BNCM: DELEX Pharma Secures $4.30 Million Contract for Newly Opened Medical Center. April 25, 2025 admin_bncm 10:11 am April 2025 — BNCM and DELEX Pharma are proud to announce that DELEX has been officially appointed as the Spot Dealer for the newly inaugurated St. Irenaeus Medical Center Inc. (SIMCI), a modern five-story, 100-bed secondary hospital strategically located in Bocaue, Bulacan. Built on a 3,800-square-meter plot, this state-of-the-art facility is designed to become a leading provider of comprehensive medical care in Central Luzon. This landmark agreement covers a US$4.30 million (Php260 million) contract and includes the supply, installation, and commissioning of cutting-edge diagnostic and interventional imaging systems from Philips, a global leader in healthcare technology. It marks a significant milestone in the ongoing efforts of DELEX to strengthen healthcare delivery in emerging regions across the Philippines. Under this contract, DELEX will provide: Philips CT Scan System – Advanced imaging technology designed for fast, accurate diagnostics with lower radiation doses, supporting a wide range of clinical applications. Philips Cath Lab – A state-of-the-art catheterization laboratory tailored for interventional cardiology and radiology procedures, ensuring real-time imaging for precision-guided treatment. Philips MRI Scanner – High-definition magnetic resonance imaging with superior image quality, patient comfort, and operational efficiency, ideal for neurology, musculoskeletal, and whole-body imaging. This partnership reflects the hospital’s commitment to delivering world-class medical care to communities in Bulacan and Central Luzon, while positioning itself as a hub for advanced diagnostic and interventional healthcare services in the region. For DELEX. this also reinforces its market presence in Luzon’s growing private healthcare sector, while showcasing our ability to deliver end-to-end medical equipment solutions — from sourcing and procurement to installation, training, and technical support. Market Context: Philippines Medical Device Sector The Philippines’ medical device market is one of the fastest-growing in Southeast Asia, projected to reach PHP 130 billion (approximately USD 2.30 billion) by 2025, driven by factors such as increased healthcare spending, hospital expansions, and rising demand for advanced medical technologies. The Luzon region, particularly the National Capital Region (NCR), accounts for over 60% of the total market share, underscoring the strategic importance of investments in this area. Government initiatives, such as the establishment of pharma-medical device ecozones in regions like Bulacan, aim to enhance manufacturing capabilities and attract foreign investments, offering incentives like tax holidays and duty-free imports. DELEX’s contract for the supply of cutting-edge diagnostic and interventional imaging systems from Philips, a global leader in healthcare technology with the new hospital aligns with these national objectives, contributing to the development of a robust healthcare infrastructure and the advancement of medical technology in the Philippines. DELEX is honored to contribute to the transformation of healthcare infrastructure in the Philippines and look forward to continuing our collaboration with healthcare institutions in driving innovation, accessibility, and patient-centered care. DELEX: A Future of Growth and Innovation With a proven track record of success, a visionary leadership team, and a strategic expansion plan that spans multiple facets of the healthcare industry, DELEX is poised to become a dominant player in the global healthcare market. As the company continues to innovate, expand, and strengthen its presence in key sectors, it remains on track to achieve its ambitious goals and deliver value to its stakeholders. The future of DELEX looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey. DELEX is committed to continuously improving the healthcare landscape, ensuring that high-quality medicines and medical devices are accessible to all. About DELEX Healthcare Group, Inc. (DELEX) DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence. For more information, visit – https://bncm.us and https://bncm.net Share this : Latest Post 25 Apr 2025 BNCM: DELEX Pharma Secures $4.30 Million Contract for Newly Opened Medical Center. 15 Apr 2025 BNCM (DELEX): The Most Undervalued Stock Poised for Explosive Growth 20 Mar 2025 Tramadol – TRAMADEX Popular Categories Strategic Partnerships Regulatory Approvals and Certifications Post-Merger Developments Mergers and Acquisitions Financial Performance Expansion Plans Community Engagement and Outreach
BNCM (DELEX): The Most Undervalued Stock Poised for Explosive Growth
In a market filled with opportunities, BNCM (DELEX) are emerging as the most undervalued stocks poised for substantial growth. BNCM is strategically positioned in the healthcare and medica; industries, offering exciting investment prospects for savvy investors looking to tap into high-growth sectors with substantial upside potential.
Tramadol – TRAMADEX
TRAMADEX is produced by Ahngook Pharmaceutical Co., Ltd, a reputable company in South Korea with a Certificate of Current Good Manufacturing Practice (cGMP). It has developed and supplied outstanding medicines for the last forty (45) years in the pharmaceutical industry.
Ketorolac – KETOROLEX
KETOROLEX is among the quality products of Delex Pharma. It is used primarily as a short-term treatment of moderate to severe pain in adults. This medication is a nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen – INTRAFEN
INTRAFEN is the first and only Ibuprofen brand in I.V. preparation launched in the Philippines in August 2018. DPII is proud in initiating the availability of INTRAFEN, as it is recognized for its significance in treating severely ill patients. Study shows that Ibuprofen has been rated as the safest conventional Nonsteroidal anti-inflammatory drug (NSAID).
Paracetamol – IFIMOL
IFIMOL is a premier brand in Paracetamol I.V. promoted in the country. It was included in the Top 200 hospital ethical Products based on Dec 2018 IQVIA Report. IFIMOL is a PREMIXED, READY-TO-USE solution containing a therapeutic dose of 1 g paracetamol for adults. It can be administered as an infusion with no side effects. Moreover, IFIMOL is considered as safest treatment for fever and pain management.
Bupivacaine in Dextrose – BUPIVAXINE
BUPIVAXINE is a local anesthetic agent of the amide type. Bupivacaine in Dextrose produces a moderate muscular relaxation of the lower extremities lasting 2-2.5 hours. The motor blockade of the abdominal muscles makes the solution suitable for performing abdominal surgery lasting 45-60 minutes. It is indicated as intrathecal spinal anesthesia in adults and children of all ages.
Linezolid – Axazolid
AXAZOLID is the first branded generic Linezolid available in the Philippine market! Axa Parenterals, the leading sterile solution producer in India, manufactures a premium and affordable brand. AXAZOLID was launched by Delex Pharma in September 2018.
Ceftazidime – Ceftazin
CEFTAZIN is one of the quality products of Delex Pharma International Inc. It is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. The product is acquired from United Biotech, which is among the multi-core companies in India. DPII has assured that the manufacturer is CGMP and ISO certified.
Ceftriaxone – Ceftrex
CEFTREX is a premium product of Delex Pharma International, Inc. manufactured by United Biotech, India.